{"id":"sulfonylureas-su","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypoglycemia"},{"rate":"10-20%","effect":"Weight gain"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL5303414","moleculeType":null,"molecularWeight":"442.49"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action leads to depolarization of the beta cell membrane, opening of voltage-dependent calcium channels, and an influx of calcium ions. The increased intracellular calcium triggers the release of insulin from secretory granules.","oneSentence":"Sulfonylureas stimulate insulin release from pancreatic beta cells by binding to and closing ATP-sensitive potassium channels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:43.124Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":"Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease","enrollment":451036},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT07332156","phase":"","title":"Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-01-01","conditions":"Type 2 Diabetes, COPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis)","enrollment":21692},{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":194},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT05073692","phase":"","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-07-01","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":241981},{"nctId":"NCT05933174","phase":"NA","title":"Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes","status":"RECRUITING","sponsor":"Ian J. Neeland, MD","startDate":"2023-10-01","conditions":"Type2diabetes","enrollment":220},{"nctId":"NCT05214573","phase":"","title":"Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-12-01","conditions":"Type 2 Diabetes, Cardiac Disease","enrollment":386301},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT05751525","phase":"","title":"Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome","status":"RECRUITING","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-07-01","conditions":"Neurodevelopmental Disorders, Intellectual Disability, Development Delay","enrollment":21},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT01986881","phase":"PHASE3","title":"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-11-04","conditions":"Type 2 Diabetes Mellitus","enrollment":8246},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes","enrollment":192},{"nctId":"NCT03433248","phase":"PHASE4","title":"Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES","status":"UNKNOWN","sponsor":"M.H.H. Kramer","startDate":"2017-11-09","conditions":"Type2 Diabetes","enrollment":66},{"nctId":"NCT03770728","phase":"PHASE3","title":"Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-01","conditions":"Type 2 Diabetes Mellitus","enrollment":312},{"nctId":"NCT04123587","phase":"PHASE4","title":"Genetic Variants Replication Study Associated With Dependence on Sulfonylurea in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2019-09-10","conditions":"Diabetes Mellitus","enrollment":58},{"nctId":"NCT03049228","phase":"","title":"In and ex Vivo Mitochondrial Function of the Heart","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2017-03-21","conditions":"Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies","enrollment":38},{"nctId":"NCT03983551","phase":"PHASE4","title":"Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2016-03-01","conditions":"Type 2 Diabetes Mellitus, Proteinuria","enrollment":101},{"nctId":"NCT02207374","phase":"PHASE3","title":"A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":601},{"nctId":"NCT00212004","phase":"PHASE4","title":"Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study)","status":"TERMINATED","sponsor":"National Cerebral and Cardiovascular Center, Japan","startDate":"2005-04","conditions":"Diabetes Mellitus, Myocardial Infarction","enrollment":630},{"nctId":"NCT01917656","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-01-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":343},{"nctId":"NCT02485132","phase":"","title":"Evaluating the True Magnitude of HYPOglycemic Events After THE Initiation of Sulfonylurea","status":"TERMINATED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2016-03","conditions":"Type 2 Diabetes","enrollment":2},{"nctId":"NCT01964950","phase":"","title":"Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-07","conditions":"Surveillance","enrollment":1101},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Diabetes Mellitus, Type 2","enrollment":4447},{"nctId":"NCT00789191","phase":"PHASE3","title":"Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":222},{"nctId":"NCT00395746","phase":"PHASE3","title":"Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT00968812","phase":"PHASE3","title":"CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1452},{"nctId":"NCT01511172","phase":"PHASE2","title":"Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT01691989","phase":"PHASE3","title":"A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-12","conditions":"Diabetes Mellitus Type 2","enrollment":197},{"nctId":"NCT02106104","phase":"PHASE4","title":"Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-03","conditions":"Type 2 Diabetes","enrollment":48},{"nctId":"NCT01871558","phase":"PHASE3","title":"Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-06","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":42},{"nctId":"NCT01278485","phase":"","title":"Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":726},{"nctId":"NCT01468181","phase":"PHASE3","title":"A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-11","conditions":"Type 2 Diabetes Mellitus","enrollment":394},{"nctId":"NCT01421459","phase":"PHASE3","title":"A Study in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-09","conditions":"Diabetes Mellitus, Type 2","enrollment":759},{"nctId":"NCT01584232","phase":"PHASE3","title":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":361},{"nctId":"NCT01204294","phase":"PHASE3","title":"Comprehensive Add on Study in Japan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-09","conditions":"Diabetes Mellitus, Type 2","enrollment":574},{"nctId":"NCT00975065","phase":"PHASE4","title":"Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":266},{"nctId":"NCT00562172","phase":"PHASE4","title":"Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Type 2 Diabetes Mellitus","enrollment":75},{"nctId":"NCT01176656","phase":"","title":"Hypoglycemia: Physician and Patient Perspectives","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Type 2 Diabetes Mellitus, Hypoglycemia","enrollment":800},{"nctId":"NCT00283049","phase":"PHASE4","title":"Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control","status":"TERMINATED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Diabetes Mellitus, Type 2","enrollment":390},{"nctId":"NCT01206712","phase":"","title":"Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"ikfe-CRO GmbH","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sulfonylureas (SU)","genericName":"Sulfonylureas (SU)","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sulfonylureas stimulate insulin release from pancreatic beta cells by binding to and closing ATP-sensitive potassium channels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}